Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Follow-Up Questions
¿Cuál es el ratio P/E de Infinity Pharmaceuticals Inc (INFIQ)?
El ratio P/E de Infinity Pharmaceuticals Inc es 0
¿Qué tal es el rendimiento del precio de la acción INFIQ?
El precio actual de INFIQ es de $0.0001, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Infinity Pharmaceuticals Inc?
Infinity Pharmaceuticals Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Infinity Pharmaceuticals Inc?
La capitalización bursátil actual de Infinity Pharmaceuticals Inc es $9076
